Bayer Stock Soars After Supreme Court Guts Core Legal Theory Behind 1000s Of Roundup Cases

Bayer AG's stock prices skyrocketed following a Supreme Court decision that struck down the central legal argument used in numerous Roundup cancer lawsuits, potentially shielding the company from thousands of claims. The 7-2 ruling favored Bayer, invalidating a $1.25 million verdict from Missouri, which had alleged that Bayer didn't warn consumers about the weedkiller's cancer risks. This ruling could have significant implications for Bayer's financial outlook and the broader legal landscape regarding product liability and cancer-causing substances.